Source: Channel NewsAsia Johnson & Johnson on Wednesday posted a 32per cent rise in fourth-quarter profit, boosted by demand for its cancer drugs Darzalex and Imbruvica. Read Full Article Share this:TwitterFacebook Related
Leave a Reply